CHD · Q2 2025 Earnings
CautiousChurch & Dwight
Reported August 1, 2025
30-second summary
30-second take: Organic sales just barely positive at +0.1% and reported revenue down 0.3% to $1.51B, but management's tone shifted materially — CEO said he is "incrementally even more positive today than I talked 90 days ago" after category consumption recovered from negative in early April to ~2.5% in Q2 and above that in July. Yet full-year organic guide held at 0-2% and Q3 adjusted EPS is guided to $0.72, a 9% YoY decline. The disconnect is the story: brand share is winning (5 of 7 power brands gained share), but tariffs, business exits, and vitamin drag keep the print ugly into Q3.
Headline numbers
EPS
Q2 FY2025
$0.94
Revenue
Q2 FY2025
$1.51B
-0.3% YoY
Gross margin
Q2 FY2025
45.0%
Operating margin
Q2 FY2025
21.0%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $1.51B | -0.3% |
| EPS | $0.94 | — |
| Gross margin | 45.0% | — |
| Operating margin | 21.0% | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment performance
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| Consumer Domestic | $1.154B | -1.4% |
| Consumer International | $0.278B | +5.3% |
| Specialty Products Division | $0.075B | -3.0% |
| Household Products | $0.65B | -0.5% |
| Personal Care Products | $0.504B | -2.6% |
Platform metrics
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| Organic Sales Growth | 0.1% |
| Domestic Organic Sales Growth | -1.0% |
| International Organic Sales Growth | 4.8% |
| Global E-commerce Sales as % of Consumer Sales | 23% |
| Cash from Operations (YTD) | $416.5M |
| Power Brands with Share Gains | 5 of 7 |
Profitability
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| Marketing Expense % of Net Sales | 10.4% |
| Adjusted SG&A % of Net Sales | 13.6% |
Management tone
The macro frame flipped from caution to mitigated caution. Three months ago, the May outlook was built around category consumption that had turned negative in early April. Q2 ended with categories at +2.5% and July came in above that. "Some of that has been mitigated" — the CEO's word for the April panic — and he is "incrementally even more positive today than I talked 90 days ago." This is a meaningful reversal for a company whose communication style typically errs flat.
Yet the guide didn't move, and that's deliberate. Management is explicitly hedging against being burned twice: "maybe it's conservative, but what we think the environment is right now, it's so volatile that there's no reason to take the full year up." Pairing improved confidence with unchanged guidance is the giveaway that the upside, if it materializes, is being deferred to Q4 commentary or 2026 framing. The evergreen model language — "I do think it is a bit of an aberration" — signals management wants investors to view 2025 as a one-year deviation, not a structural reset.
The vitamin business is being re-framed in real time. Previously a drag requiring decisive action; this quarter it's "mixed results" with "green shoots" in multivitamin, plus an explicit strategic review weighing JV, partnership, or divestiture. The candor that vitamins consume "disproportionate org resources relative to benefit" is the strongest signal yet that exit is the likeliest outcome — but management committed to maintaining full innovation and promotional support during the review, which limits near-term EPS relief.
Tariff disclosure became more granular and more dynamic. Q2 talk was about an embedded full-year impact. Q2 commentary is now specific: $60M gross 12-month exposure, ~$50M run rate after recent policy changes, with Korea, Thailand, Vietnam, and Europe representing 73% of remaining exposure. The CFO described overnight changes to the run-rate estimate — useful color, but it underlines that the FY guide is built on shifting sand.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Filippo Falorni · Citi
Asked for breakdown of $30 million tariff impact by country and expectations for commodity/input cost inflation in the basket going forward.
Management identified Korea, Thailand, Vietnam, and Europe as top tariff-impacted regions (73% of remaining exposure). Noted tariff estimates have shifted from $60M to ~$50M run rate due to overnight policy changes. Expect to manage through productivity programs and targeted pricing. Broader inflation expected to remain slightly elevated but manageable.
Robert Moscow · TD Cowan
Asked about international business growth strategy, specifically performance of expanded US brands (Hero, TheraBreath) and whether slower macro conditions are impacting new brand adoption.
International growing mid- to high-single digits, driven by local brands (Sterimar, Batiste) and recent acquisitions (Hero, TheraBreath). Hero achieved 50 countries in 12 months. Despite macro headwinds in many international markets, company brands outperforming competitors who are declining. Early innings for acquisition growth; pursuing further M&A opportunities in Europe and China.
Kevin Grundy · BNP Paribas
Asked about promotional environment assumptions for back half, noting discrepancy between company's benign tone and competitor signals plus Nielsen data showing promotional ramp, particularly in household/Arm & Hammer. Also asked about vitamin business: how to balance speed of divestiture with asset value and risk of further deterioration.
Promotions in Q1-Q2 within historical norms; back-half promotional plans already locked in for several quarters ahead. Laundry gaining share in June/July driven by innovation (Deep Clean) alongside promotions. For vitamins, will operate as long-term owner (maintaining innovation, pricing, promotional support) while exploring strategic alternatives, balancing timeliness against value realization and retail confidence.
Filippo Falorni · Citi
Follow-up on tariff impact: which countries are most affected within the $30 million estimate and clarification on China exposure.
After managing China tariff impacts, remaining exposure concentrated in Korea, Thailand, Vietnam, and Europe (73% of residual). Tariff estimates fluid—changed overnight from $60M to closer to $50M run rate, demonstrating agility. Few product lines/countries drive majority of exposure; will manage through productivity and targeted pricing.
Kevin Grundy · BNP Paribas
Follow-up on vitamin business: how to balance speed of divestiture decision against asset value and avoiding further business deterioration during strategic review process.
Will operate vitamin brands (Vitifusion, Little Critters) as if owning forever—maintaining full innovation, promotional, and pricing support. Will communicate continued commitment to retailers. However, acknowledged vitamins are small business requiring disproportionate org resources relative to benefit, which factors into strategic review decision.
What to watch into next quarter
Whether Q3 adjusted EPS lands at or above the $0.72 guide — a beat here would validate the "conservative on purpose" framing; a miss would show the back-half setup was already tight before tariffs shifted.
Vitamin strategic review outcome or timeline — JV, divestiture, or rightsizing decision; watch for a Q3 update given the "disproportionate resources" admission in Q&A.
Domestic organic sales growth turning positive — Q2 printed -1.0%; management's confidence hinges on this inflecting with July category data. Watch for Q3 domestic organic above zero.
Batiste consumption trajectory — management committed to a return to growth; -7% in Q2 needs to narrow visibly in Q3 scanner data to validate that the supply/competitive issues were transitory.
Tariff run-rate revision — the $50-60M range moved overnight once; watch for whether mitigation actions (productivity, targeted pricing) bring the realized number below $50M and how much pricing CHD is willing to take.
FY guide revision at Q3 — if July strength persists, management's "no reason to take the full year up" stance becomes harder to defend. A Q3 raise would confirm the inflection; another reaffirmation would suggest momentum stalled.
Sources
- Church & Dwight Q2 2025 press release (SEC 8-K Ex. 99.1), filed August 1, 2025 — https://www.sec.gov/Archives/edgar/data/313927/000095017025101104/chd-ex99_1.htm
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.